Date: 2011-03-20
Type of information:
phase: 2
Announcement: results
Company: Genentech, a member of the Roche group (USA - Switzerland)
Product: vismodegib
Action mechanism: This Hedgehog Pathway Inhibitor is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened.
Disease: advanced basal cell carcinoma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: Genentech, a member of the Roche Group announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell. The study met its primary endpoint (overall response rate), of showing vismodegib shrank tumors in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib. A detailed safety assessment is ongoing.
Data from the study will be submitted for presentation at a future medical meeting.
Genentech is also evaluating vismodegib in a Phase II trial in people with operable forms of basal cell carcinoma, which opened in October 2010.
